Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CK Life Sciences International Holdings (OTCPK:CKLSF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CK Life Sciences International Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was $1,454.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CK Life Sciences International Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings EV-to-EBIT Related Terms
CK Life Sciences International Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings EV-to-EBIT Chart
CK Life Sciences International Holdings Annual Data
For the Biotechnology subindustry, CK Life Sciences International Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings EV-to-EBIT vs Biotechnology Industry
CK Life Sciences International Holdings's current Enterprise Value is $1,474.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CK Life Sciences International Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (CKLSF) has a EV-to-EBIT of 46.12 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CK Life Sciences International Holdings and its competitors. This is 38% above median its historical median of 33.53. Over the past decade, CK Life Sciences International Holdings' EV-to-EBIT has ranged from 13.53 to 61.62. According to the industry distribution chart, CK Life Sciences International Holdings ranks #304 out of 372 companies in the Biotechnology industry, placing it in the top 81.7%.
Is CK Life Sciences International Holdings' EV-to-EBIT too high?
CK Life Sciences International Holdings' current EV-to-EBIT of 46.12 is 38% above median its 10-year median of 33.53. Over the past 10 years, this metric has ranged from a low of 13.53 to a high of 61.62. The Biotechnology industry median EV-to-EBIT is 13.35. CK Life Sciences International Holdings' value of 46.12 is 245.5% above this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #304 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Scoreâ„¢ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #304 out of 372 companies for EV-to-EBIT. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median EV-to-EBIT is 13.35. CK Life Sciences International Holdings' value of 46.12 is 245.5% above this benchmark. Historically, CK Life Sciences International Holdings' own EV-to-EBIT has ranged from 13.53 to 61.62 over the past decade. While the company's 10-year median is 33.53 vs. the industry median of 13.35, CK Life Sciences International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current EV-to-EBIT of 46.12 is 245.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current EV-to-EBIT is 46.12, which is 38% above median its own 10-year median of 33.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current EV-to-EBIT of 46.12. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current EV-to-EBIT is 46.12, which is 38% above median its 10-year median of 33.53 and 245.5% above the Biotechnology industry median of 13.35. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current EV-to-EBIT is 46.12 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
EV-to-EBIT: 46.12 (38% above median its 10-year median of 33.53)
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
Industry Position: 245.5% above the Biotechnology median (#304 of 372)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
